Collegium to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Collegium (Nasdaq: COLL) will participate in multiple investor conferences the week of March 9–11, 2026 in Miami, FL, including Leerink Partners Global Healthcare, Jefferies Biotech on the Beach, The Citizens Life Sciences Conference, and a Barclays fireside chat on March 11 at 9:00 a.m. ET.
A live webcast of the Barclays fireside chat will be available via the Investors section of the company website and a replay will be archived for 90 days.
Details
News Market Reaction – COLL
On Mar 2, the day this news came out, COLL closed 0.17% below the previous close.
Data tracked by StockTitan Argus for the Mar 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:
Leerink Partners Global Healthcare Conference
Monday, March 9, 2026
Miami, FL
Jefferies Biotech on the Beach Summit
Tuesday, March 10, 2026
Miami, FL
The Citizens Life Sciences Conference
Tuesday, March 10, 2026
Miami, FL
Barclays 28th Annual Global Healthcare Conference
Fireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ET
Miami, FL
A live webcast of the fireside chat will be available via the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.
Investor Contacts:
Ian Karp
Head of Investor Relations
ir@collegiumpharma.com
Danielle Jesse
Director, Investor Relations
ir@collegiumpharma.com
Media Contact:
Jessica Cotrone
Senior Vice President, Corporate Communications & Corporate Affairs
communications@collegiumpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.